JPMorgan Sees Pickup in Biotech M&A in 2014

Your next video will start in

Recommended Videos

  • Info

  • Comments


Jan. 15 (Bloomberg) -- Olivia Sterns reports on biotech deals on Bloomberg Television's "Money Moves." (Source: Bloomberg)

Last year was certainly a red-hot year for the biotech sector.

Will 2014 also be one?

They have a vested interest -- why question mark there has been such a run-up in biotech stocks.

When they stabilize -- the other reason they're going to look for these golden acquisitions is because they are facing patent expirations and have to figure out some way to generate -- they need to feed the pipeline.

Already in 2014, we are not at the end of the month, already two big deals.

Ge agreed to by --uy thermos or.


You talked about whether glaxo would be buying other companies.

They were actually doing divestments.

Those are two consumer drink brands that were sold.

I put this question to them.

Here at the conference, you're hearing a lot of chatter about people looking at things.

I suspect more investments and reshaping of businesses rather than large-scale acquisitions.

He thinks glaxo will be getting smaller over the course of the next year.

The big reason -- they have a lot of their own pipeline that they need to focus on.

Last year, they got five new drugs approved.

Not necessarily through buying.

We appreciate it.

This text has been automatically generated. It may not be 100% accurate.


BTV Channel Finder


ZIP is required for U.S. locations

Bloomberg Television in   change